Evidence map›Paper›PMID 29783988›Full record

ArticleMolecular neurodegeneration2018

Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease.

Charles R Schutt, Howard E Gendelman, R Lee Mosley

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. The Progress of Active Immunotherapy for Parkinson's Disease.International journal of molecular sciences · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. scDual-Seq ofFrontiers in immunology · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Charles R SchuttDepartment of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, USA.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, USA.
R Lee MosleyDepartment of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, USA. rlmosley@unmc.edu.ORCID 0000-0002-4241-6149
University of Nebraska Medical Center · USNebraska Medical Center · US

Funding

Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BUCH, SHILPA J., FOX, HOWARD S · 2000 to 2021
$37.7M
Targeted Neuro Protection of HIV-1 Associated Neurologic DiseaseP01MH064570 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 2001 to 2014
$19.4M
Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2010 to 2019
$16.8M
Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
Proteomics CoreP01NS043985 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2003 to 2012
$11.8M
Role of EAAT2 and AEG-1 in Astrocyte Dysfunction and NeurodegenerationP01NS031492 · NINDS · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI FISHER, PAUL B · 1993 to 2007
$10.9M
Nanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7M
SMART HANDR01AG043540 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E, POLUEKTOVA, LARISA Y · 2013 to 2017
$3.1M
Blood Brain Barrier Physiology and HIV DementiaR37NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E. · 2001 to 2007
$2.7M
T Cell-Mediated Neurodegeneration in Parkinson's DiseaseR01NS070190 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI MOSLEY, R LEE · 2010 to 2014
$1.8M
NIA NIH HHS AG043540NIA NIH HHS R01 AG043540NIDA NIH HHS DA028555NIDA NIH HHS P01 DA028555NIMH NIH HHS MH062261NIMH NIH HHS MH64570NIMH NIH HHS P01 MH064570NIMH NIH HHS P30 MH062261NINDS NIH HHS NS034239NINDS NIH HHS NS070190NINDS NIH HHS NS31492NINDS NIH HHS NS36126NINDS NIH HHS NS43985NINDS NIH HHS P01 NS031492NINDS NIH HHS P01 NS043985NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126NINDS NIH HHS R01 NS070190University of Nebraska Medical Center Doctroal Fellowship
6 · The paper itself

Abstract

backgroundAdministration of granulocyte-macrophage colony-stimulating factor (GM-CSF) increases regulatory T cell (Treg) number and function with control of neuroinflammation and neuronal protection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease (PD). Recently, we demonstrated in an early phase 1 clinical trial that GM-CSF also improves motor skills in PD patients. However, the mechanisms of Treg induction and its effects on neuroprotective responses remain unknown. As GM-CSF induces tolerogenic dendritic cells (DCs) that in turn convert conventional T cells to Tregs, the pathways for DC induction of Tregs were assessed.

methodsFollowing differentiation, bone marrow-derived dendritic cells (BMDCs) were cultured in media or GM-CSF with or without post-culture stimulation with nitrated α-synuclein (N-α-Syn). Expression of cell surface co-stimulatory molecules and proinflammatory cytokines, and induction of Tregs were evaluated. The neuroprotective capacity of tolerogenic BMDCs was assessed by adoptive transfer to MPTP-intoxicated mice. The extent of neuroinflammation and numbers of surviving dopaminergic neurons were assessed in relation to Treg numbers.

resultsCo-culture of differentiated BMDCs with conventional T cells led to Treg induction. Stimulation of BMDCs with N-α-Syn increased expression of co-stimulatory molecules and proinflammatory cytokines, with modest increases in Treg numbers. In contrast, continued culture of BMDCs with GM-CSF modestly altered expression of co-stimulatory molecules and proinflammatory cytokines and chemokines, but decreased Treg induction. Continued culture in GM-CSF and combined stimulation with N-α-Syn reduced Treg induction to the lowest levels. Adoptive transfer of tolerogenic BMDCs to MPTP-intoxicated mice increased splenic Tregs, attenuated neuroinflammatory responses, and protected nigrostriatal dopaminergic neurons.

conclusionsGM-CSF acts broadly to differentiate DCs and affect immune transformation from effector to regulatory immune responses. DCs skew such immune responses by increasing Treg numbers and activities that serve to attenuate proinflammatory responses and augment neuroprotection.

Indexed as

Adoptive TransferAnimalsBone Marrow CellsCell DifferentiationDendritic CellsGranulocyte-Macrophage Colony-Stimulating FactorMaleMiceMice, Inbred C57BLParkinsonian DisordersT-Lymphocytes, RegulatoryGranulocyte-Macrophage Colony-Stimulating FactorDCsDendritic cellsMiceMPTPNeurodegenerationNeuroinflammationParkinson’s diseaseRegulatory T cellsTregs

Identifiers

PMID29783988
PMCPMC5963189
OpenAlexW2807589140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.